Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

BioMarin Announces 3 Platform and 15 Poster Presentations at 13th International Congress of Inborn Errors of Metabolism 2017

Posted on: 06 Sep 17

SAN RAFAEL, Calif., Sept. 5, 2017 /PRNewswire/ -- BioMarin (Nasdaq:BMRN) announced that the company will present data in three platform presentations and fifteen poster presentations at the 13th International Congress of Inborn Errors of Metabolism (ICIEM) being held September 5-8, 2017 in Rio de Janeiro, Brazil. Presentations span a range of areas in rare genetic diseases, including neuronal ceroid lipofuscinosis type 2 (CLN2) disease, phenylketonuria (PKU) and mucopolysacchardosis (MPS).

Platform presentations include preliminary safety and pharmacodynamic response data from a Phase 1/2 study of ICV BMN 250, a novel enzyme replacement therapy for the treatment of Sanfilippo B (MPS IIIB), a long-term safety and efficacy analysis of cerliponase alfa to treat children with CLN2 disease, as well as updated five-year safety and efficacy data evaluating pegvaliase to treat adults with PKU.

Listing of Posters and Presentations Related to BioMarin Products and Programs at the 13th International Congress of Inborn Errors of Metabolism (All times are local)

For more information:

Editor's Details

Mike Wood

Last updated on: 06/09/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.